Wolfgang Brysch President of the Board of MetrioPharm AG:
MetrioPharm had a good start into 2015. Before last year's end we filed the application for our first clinical Study in man (Phase I) for MP1032 with the German regulatory authority BfArM (Bundesamt feur Arzneimittel und Medizinprodukte). We are expecting a decision by beginning of April. If the authority does not require any amendments, we will be set to include our first study subjects in April. We will keep you posted as soon as we get an official response from BfArM.
Also recently, MetrioPharm was awarded a research grant by the ZIM Cooperative Network Initiative of the German Department of Trade and Industry (see below). With this cooperation project, we are able to expand with our pipeline compounds into the attractive field of surface functionalization for medical implants. This cooperative project is so far the first and only application that passed the application criteria with respect to level of innovation and market potential as required by this ZIM Network Initiative. Apart from the valuable grant, this successful application also serves as an external validation of MetrioPharm's pipeline and state of technical development.
Another piece of positive news arrived from the US Patent Office in the form of a notice of allowance for one of our pending Patent applications (No. US2014/0303169A1).
In January, there was also a change in our investor relations position. Mrs. Joana Loens has moved for private reasons from Berlin to Frankfurt and thus left the company. While we are happy for Joana and the new perspectives in her life, we regret losing her for our team and as primary contact for our shareholders. Nevertheless our entire team retains relations of friendship to Joana and we all wish her the very best for her future.
Until we find a permanent successor for Joana, Sandra Meissner from our Berlin office will take care of investor contacts.
With warm regards Wolfgang Brysch
President of the Board of MetrioPharm AG
MetrioPharm's MP-Cap Collaboration Project gets R&D grant from German Department of Trade and Industry
Beginning in March 2015, the German R&D Center of MetrioPharm in Berlin will be supported by the renowned ZIM collaboration network of the German Department of Trade and Industry. In the scope of this ZIM collaboration, MetrioPharm and Munich based NanoScape AG co-develop a new generation of drug eluting stents. These implants will not only widen obstructed coronary arteries but will be able to elute drugs which prevent the re-stenosis of the stented vessel for extended periods. This innovative, nano-based drug releasing coating will last up to five times longer than currently used coatings. Thus stented vessels can be protected against re-stenosis over much more extended periods until the stent is completely healed-in.
"The safety and tolerability of the new stents is our main objective. It is designed to heal-in before proliferation and scarring of the vessel lining can occur" commented Dr. Claudia Van Laak, MetrioPharm's head of this development project.
Stents and other implants can become safer, assuring more reliable therapeutic success rates by sustained elution of drugs from MetrioPharm's pipeline.
This project will be financially supported by ZIM for a period of two years.
With this newsletter, I bid goodbye to you. At the beginning of the center of my life has shifted to Frankfurt. With this change, I also had to change jobs. I was delighted to be part of MetrioPharm's progress and to be the main contact to you during this time. My thanks go to the MetrioPharm team and to you. It was an exciting time in Berlin.
I wish all the best to MetrioPharm AG, the entire team and also you, our loyal shareholders and success for the promising future of the company.
Very sincerely yours